Alaunos Therapeutics, Inc. (TCRT)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Alaunos Therapeutics, Inc. reported revenue of $5.0K, down 50.0% from the prior year. The company ran a net loss, with a net margin of -83520.0%. It held $2.97M in total assets against $813.0K in total liabilities.
Key ratios (FY2025)
-84500.0%
Operating margin
-83520.0%
Net margin
-194.0%
Return on equity
-50.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0K | $10.0K | $5.0K | $2.92M | $398.0K | $0 | — | $146.0K | $6.39M | $6.86M |
| Operating Income | -$4.22M | -$4.81M | -$34.27M | -$35.10M | -$77.55M | -$80.36M | -$57.86M | -$53.91M | -$53.49M | -$165.31M |
| Net Income | -$4.18M | -$4.68M | -$4.68M | -$37.73M | -$78.75M | -$79.98M | -$117.80M | -$53.12M | -$54.32M | -$165.30M |
| EPS (Diluted) | $-2.20 | $-2.92 | $-21.97 | $-2.61 | $-0.37 | $-0.38 | $-0.70 | $0.96 | $-0.53 | $-1.32 |
| Total Assets | $2.97M | $2.75M | $8.26M | $64.94M | $94.86M | $146.34M | $109.11M | $95.05M | $105.61M | $106.35M |
| Total Liabilities | $813.0K | $692.0K | $1.96M | $26.38M | $36.81M | $22.36M | $14.10M | $9.49M | $58.42M | $58.33M |
| Shareholders' Equity | $2.15M | $2.06M | $6.31M | $38.55M | $58.06M | $123.98M | $95.01M | $85.56M | -$96.81M | -$77.30M |
| Cash & Equivalents | $1.39M | $1.09M | $6.06M | $39.06M | $76.05M | $115.07M | $79.74M | $61.73M | $70.95M | $81.05M |
| Operating Cash Flow | -$2.87M | -$4.97M | -$30.14M | -$29.23M | -$61.47M | -$57.01M | -$40.85M | -$49.46M | -$54.67M | -$58.33M |
| Capital Expenditures | $98.0K | $0 | $197.0K | $216.0K | $3.32M | $9.78M | $284.0K | $459.0K | $737.0K | $551.0K |
| Shares Outstanding | 2.35M | 1.60M | 1.60M | 16.03M | 216.13M | 214.59M | 181.80M | 161.07M | 142.66M | 132.38M |